These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Evaluating pharmacists' views, knowledge, and perception regarding generic medicines in New Zealand. Babar ZU; Grover P; Stewart J; Hogg M; Short L; Seo HG; Rew A Res Social Adm Pharm; 2011 Sep; 7(3):294-305. PubMed ID: 21272551 [TBL] [Abstract][Full Text] [Related]
23. Community pharmacists' role in benzodiazepine supply in Ireland: a questionnaire of pharmacists' views and experiences. Cadogan CA; Ryder SA Int J Pharm Pract; 2015 Dec; 23(6):415-22. PubMed ID: 25756294 [TBL] [Abstract][Full Text] [Related]
24. Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada. Abbott R; Edwards S; Whelan M; Edwards J; Dranitsaris G J Oncol Pharm Pract; 2014 Feb; 20(1):29-39. PubMed ID: 24103897 [TBL] [Abstract][Full Text] [Related]
25. Community pharmacists' prescription intervention practices--exploring variations in practice in Norwegian pharmacies. Mandt I; Horn AM; Ekedahl A; Granas AG Res Social Adm Pharm; 2010 Mar; 6(1):6-17. PubMed ID: 20188324 [TBL] [Abstract][Full Text] [Related]
26. New York State pharmacists' attitudes toward needle and syringe sales to injection drug users before implementation of syringe deregulation. Linas BP; Coffin PO; Backes G; Vlahov D J Urban Health; 2000 Dec; 77(4):768-80. PubMed ID: 11194316 [TBL] [Abstract][Full Text] [Related]
27. Relationship between attitudes toward mental illness and provision of pharmacy services. Rickles NM; Dube GL; McCarter A; Olshan JS J Am Pharm Assoc (2003); 2010; 50(6):704-13. PubMed ID: 21071314 [TBL] [Abstract][Full Text] [Related]
28. The role of the community pharmacist in drug abuse: a comparison of service provision between Northern Ireland and England/Wales. Fleming GF; McElnay JC; Hughes CM; Sheridan J; Strang J Pharm World Sci; 2001 Feb; 23(1):13-6. PubMed ID: 11344585 [TBL] [Abstract][Full Text] [Related]
29. [Opioid agonist therapy and the German Narcotic Drugs Prescription Ordinance from the pharmacist's perspective]. Kuhn S; Lehmann K; Schulte B; Verthein U Z Evid Fortbild Qual Gesundhwes; 2022 Feb; 168():57-64. PubMed ID: 34955439 [TBL] [Abstract][Full Text] [Related]
30. Organizational factors influencing pharmacy practice change. Doucette WR; Nevins JC; Gaither C; Kreling DH; Mott DA; Pedersen CA; Schommer JC Res Social Adm Pharm; 2012; 8(4):274-84. PubMed ID: 21958467 [TBL] [Abstract][Full Text] [Related]
31. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Nielsen S; Dietze P; Dunlop A; Muhleisen P; Lee N; Taylor D Drug Alcohol Rev; 2007 Mar; 26(2):143-51. PubMed ID: 17364849 [TBL] [Abstract][Full Text] [Related]
32. Pharmacists' knowledge of and attitudes toward opioid pain medications in relation to federal and state policies. Joranson DE; Gilson AM J Am Pharm Assoc (Wash); 2001; 41(2):213-20. PubMed ID: 11297334 [TBL] [Abstract][Full Text] [Related]
33. Community pharmacists' attitudes toward and professional interactions with users of psychiatric medication. Phokeo V; Sproule B; Raman-Wilms L Psychiatr Serv; 2004 Dec; 55(12):1434-6. PubMed ID: 15572574 [TBL] [Abstract][Full Text] [Related]
34. Evaluating community pharmacists' perceptions of future generic substitution policy implementation: a national survey from Malaysia. Chong CP; Hassali MA; Bahari MB; Shafie AA Health Policy; 2010 Jan; 94(1):68-75. PubMed ID: 19762106 [TBL] [Abstract][Full Text] [Related]
35. Individual medication management system (IMMS) implementation in pharmacists' opinion. Waszyk-Nowaczyk M; Lawicki S; Michalak M; Simon M Acta Pol Pharm; 2014; 71(3):509-14. PubMed ID: 25265831 [TBL] [Abstract][Full Text] [Related]
36. What to do when presented with a prescription from another European country: insight from a qualitative study of pharmacists in England. Knai C; Saliba V; Davies J; McKee M; Khoshaba B; Lago E; San Miguel L Int J Pharm Pract; 2014 Apr; 22(2):112-8. PubMed ID: 23849254 [TBL] [Abstract][Full Text] [Related]
37. Analysis of community chain pharmacists' interventions on electronic prescriptions. Warholak TL; Rupp MT J Am Pharm Assoc (2003); 2009; 49(1):59-64. PubMed ID: 19196598 [TBL] [Abstract][Full Text] [Related]
38. Opioids for managing patients with chronic pain: community pharmacists' perspectives and concerns. Greenwald BD; Narcessian EJ J Pain Symptom Manage; 1999 May; 17(5):369-75. PubMed ID: 10355216 [TBL] [Abstract][Full Text] [Related]
39. Pharmaceutical care in a community-based practice setting in Jordan: where are we now with our attitudes and perceived barriers? Aburuz S; Al-Ghazawi M; Snyder A Int J Pharm Pract; 2012 Apr; 20(2):71-9. PubMed ID: 22416931 [TBL] [Abstract][Full Text] [Related]
40. Physician beliefs and attitudes toward collaboration with community pharmacists. Kucukarslan S; Lai S; Dong Y; Al-Bassam N; Kim K Res Social Adm Pharm; 2011 Sep; 7(3):224-32. PubMed ID: 21272527 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]